No abstract

No abstract

No abstract

No abstract

People’s proclivity for favoring their ingroups over outgroups has negative consequences for individuals, groups, and societies. Social psychologists have explored a variety of techniques to reduce these intergroup biases. Emerging research suggests that mindfulness may be effective for this purpose. Mindfulness is defined as present-moment attention and awareness with an accepting attitude, and it is often cultivated through meditation. Our systematic review of the mindfulness-intergroup literature suggests that, across the heterogeneity of paradigms, mindfulness attenuates intergroup bias. Supporting this supposition, for all studies in the current review, regardless of operationalization of mindfulness (i.e., mindfulness-based intervention, brief mindfulness induction, expert meditators, dispositional mindfulness), the overall effect size was g = +.29 ( k-number of studies = 36; 95% CI [0.20, 0.39]; Z = 5.94, p < .0001), suggesting a small but significant effect of mindfulness on improved levels of intergroup bias. In the current work, we review the eligible studies and their findings in detail and conclude by discussing critical issues and implications for future research.

No abstract

No abstract

Rationale: Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research.Objective: In this article, we review the many methodological challenges of conducting psychedelic clinical trials and provide recommendations for improving the rigor of future research.Results: We found that although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias. The subjective effects of a high-dose psychedelic are often so pronounced that it is difficult to mask participants to their treatment condition; the significant hype from positive media coverage on the clinical potential of psychedelics influences participants’ expectations for treatment benefit; and participant unmasking and treatment expectations can interact in such a way that makes psychedelic therapy highly susceptible to large placebo and nocebo effects. Specific recommendations to increase the success of masking procedures and reduce the influence of participant expectancies concern study development, participant recruitment and selection, incomplete disclosure of the study design, choice of active placebo condition, as well as the measurement of participant expectations and masking efficacy.Conclusion: Incorporating these design elements is intended to reduce the risk of bias in psychedelic clinical trials and thereby increase the ability to discern treatment-specific effects of psychedelic therapy